Central Line-associated Bloodstream Infection Prevention Using TauroLock-Hep100 in Pediatric Oncology Patients.

Inclusion Criteria: * Age between 0 - \<19 years * Radiological, cytological or histological proven paediatric malignancy (hematologic, solid, and neurologic malignancies) * Tunnelled external central venous access device or totally implantable venous access port to be inserted at the Princess Máxima Center for Pediatric Oncology * Planned central venous access device insertion of \>90 days * Written consent signed according to local law and regulations * Parents/guardians or patient are willing and able to comply with the trial procedure Exclusion Criteria: * A previous central venous access device removed \< 12 months ago. * Expected treatment for a majority of the follow-up time in a different hospital than the Princess Maxima Center for pediatric oncology in the first 90 days of inclusion resulting in difficulties/the inability to visit the Princess Maxima Center at least once every 3 weeks. * Primary immunological disorder * Contra indications: known hypersensitivity to taurolidine, citrate or heparin, and a history of heparin-induced thrombocytopenia. * Documented bacteremia in the period from 24h before catheter insertion until inclusion